Filing Details

Accession Number:
0001209191-19-037487
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-06-17 18:41:18
Reporting Period:
2019-06-13
Accepted Time:
2019-06-17 18:41:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1080709 Arena Pharmaceuticals Inc ARNA Pharmaceutical Preparations (2834) 232908305
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219018 Oliver Fetzer C/O Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego CA 92121
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2019-06-13 2,654 $0.00 5,704 No 4 A Direct
Common Stock Disposition 2019-06-14 1,495 $55.88 4,209 No 4 S Direct
Common Stock Disposition 2019-06-14 30 $56.64 4,179 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Acquisiton 2019-06-13 5,000 $0.00 5,000 $56.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
5,000 2026-06-13 No 4 A Direct
Footnotes
  1. The amount represents restricted stock units that vest in full on the earliest of June 13, 2020, or the date of Arena's next annual meeting of stockholders. The shares underlying the restricted stock units will be issued upon vesting of the restricted stock units.
  2. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan established by the reporting person.
  3. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.49 to $56.48, inclusive. The reporting person undertakes to provide Arena Pharmaceuticals, Inc., any security holder of Arena Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
  4. The options vest in 12 equal monthly installments (except as otherwise necessary to avoid vesting of a fractional share) over one year beginning on July 13, 2019, and are exercisable once vested.